My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

53.43 +0.66 (+1.26%)

Streaming Delayed Price Updated: 1:05 PM EST, Jan 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

34 35 Next >

OTC Markets 2021 Annual Data Review Highlights A Record 60% $ Volume Increase ↗

March 07, 2022

Photo by Sophie Bakes on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The...

Via Benzinga

The Ruble Is Rubble ↗

March 03, 2022

MSCI says Russian companies are

Via Talk Markets

Holiday Over ↗

February 22, 2022

China is busily avoiding taking sides between Ukraine and Russia.

Via Talk Markets

Roche And AstraZeneca Settle Ultomiris Patent Lawsuit ↗

February 22, 2022

Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly...

Via Benzinga

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial ↗

February 18, 2022

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab...

Via Benzinga

Biotech Stocks Are Down And Out; Can These 2022 Trends Save Them? ↗

February 17, 2022

Can the formerly red-hot biotech segment return to its previous glory?

Via Investor's Business Daily

Large Cap Biopharma- Well Positioned For Choppy Markets ↗

February 14, 2022

If the past week is any indicator large-cap biopharma stocks are a good place to hide from the turbulence of 2022 markets.

Via Talk Markets

These OTC Securities Reported The Most Trading Volume In January – With Possible Sustained Interest In International Operators ↗

February 14, 2022

Photo from Jason Briscoe on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Can Anyone Challenge Pfizer's Covid Dominance? Why These Biotechs Say Yes ↗

February 11, 2022

Drug behemoth Pfizer was the first to launch a Covid antiviral pill — but a pack of small biotech stocks are already nipping at its heels.

Via Investor's Business Daily

New Two-Year Data for Genentech’s Vabysmo and Susvimo Reinforce Potential to Maintain Vision With Fewer Treatments for People With Two Leading Causes of Vision Loss

February 11, 2022

From Genentech

Via Business Wire

Why Are Seagen Shares Sinking Today? ↗

February 10, 2022

Seagen Inc (NASDAQ: SGEN) reported Q4 revenues

Via Benzinga

Dampening Exuberance ↗

February 09, 2022

The bond sell-off halted today but the Fed's plans mean this will resume.

Via Talk Markets

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More ↗

February 06, 2022

Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came...

Via Talk Markets

The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More ↗

February 06, 2022

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big...

Via Benzinga

Global Diversification: Switzerland And The Philippines ↗

February 05, 2022

One way to avoid or defend against slowing growth in the US is to own positions in other countries. There is likely a fund for almost any developed country you can think of that owns a basket of stocks...

Via Talk Markets

Cathie Wood's Ark Invest Sheds Stake In This Large-Cap Pharma Ahead Of Earnings ↗

February 05, 2022

Big pharma reporting season was muted, with the quarterly results and guidance coming in mixed.

Via Benzinga

A News Blizzard ↗

February 04, 2022

Markets are still down despite very encouraging news in January when 467,00 new hires got jobs.

Via Talk Markets

The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation ↗

February 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Roche Expects Slower FY22 Sales Growth On Lower Demand For COVID-19 Tests ↗

February 03, 2022

Roche Holdings AG's (OTC: RHHBY) FY21 sales increased 8% Y/Y (9% on a constant currency basis) to CH

Via Benzinga

Novartis Expects FY22 Sales, Profit Growth; Sandoz Review Continues ↗

February 02, 2022

Novartis AG (NYSE: NVS) reported a Q4 net income of $16.31 billion, up from $2.1 billion the previous year,

Via Benzinga

World Markets News for Tuesday ↗

February 01, 2022

Exxon is splitting into 3 with its new restructuring move: upstream; chemicals; and low-carbon.

Via Talk Markets

Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab ↗

February 01, 2022

Biogen Inc (NASDAQ: BIIB) has

Via Benzinga

The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News ↗

January 31, 2022

The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.

Via Benzinga

FDA Approves First Injectable Eye Medicine For Vision Loss Disorder - Genentech's Vabysmo ↗

January 31, 2022

The FDA has approved Genentech's, a unit of

Via Benzinga

FDA Approves Genentech’s Vabysmo, the First Bispecific Antibody for the Eye, to Treat Two Leading Causes of Vision Loss

January 28, 2022

From Genentech

Via Business Wire

Drug Troubles ↗

January 28, 2022

The drug sector has both good news and bad.

Via Talk Markets

Genentech's Evrysdi Application Under FDA Priority Review For Use In Babies Below 2 Months ↗

January 25, 2022

The FDA has granted priority review for Genentech's, a unit of Roche Holdings AG (OTC: RHHBY) supplemental marketing application for Evrysdi (...

Via Benzinga

These OTC Securities Had the Most Trading Activity in December ↗

January 25, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be i...

Via Benzinga

Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)

January 25, 2022

From Genentech

Via Business Wire

The Lancet Publishes Studies Showing Genentech’s Faricimab Improved and Maintained Vision in Two Leading Causes of Vision Loss, Extending Time Between Treatments up to Four Months

January 24, 2022

From Genentech

Via Business Wire

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.